NDUFV1
ENSG00000167792
Target class
Enzyme
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-51K
- Target name
- NDUFV1
- Gene name
- NADH:ubiquinone oxidoreductase core subunit V1
- Gene symbol
- NDUFV1
- Protein name
- NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial (NDUFV1) (EC 7.1.1.2) (Complex I-51kD) (CI-51kD) (NADH dehydrogenase flavoprotein 1) (NADH-ubiquinone oxidoreductase 51 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 240.57
- Tissue specificity (Gini)
- 0.159
- Tissue specificity (tau)
- 0.392
- KEGG gene identifiers
- hsa:4723
- Protein interaction confidence
- 0.91318
- Protein interaction partners
- 139
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 67612554
- Start position
- 67605653
- Chromosome
- 11
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Cytosol
- Mitochondria
- Tissue specificity (tau)
- 0.391853
- Expression inequality (Gini)
- 0.158877
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 240.57
- Heart - Left Ventricle
- 236.29
- Cells - EBV-transformed lymphocytes
- 233.99
- Brain - Cerebellum
- 232.98
- Muscle - Skeletal
- 222.56
Expression in transcripts per million
- Brain - Cerebellar Hemisphere240.57
- Heart - Left Ventricle236.29
- Cells - EBV-transformed lymphocytes233.99
- Brain - Cerebellum232.98
- Muscle - Skeletal222.56
- Thyroid210.16
- Heart - Atrial Appendage203.21
- Cervix - Endocervix194.66
- Ovary190.67
- Kidney - Medulla179.34
- Cervix - Ectocervix178.18
- Uterus174.86
- Nerve - Tibial174.72
- Fallopian Tube170.83
- Colon - Transverse167.73
- Testis164.94
- Brain - Frontal Cortex (BA9)164.12
- Skin - Sun Exposed (Lower leg)160.46
- Spleen153.97
- Vagina153.14
- Brain - Cortex152.46
- Skin - Not Sun Exposed (Suprapubic)151.86
- Bladder150.38
- Adrenal Gland150.24
- Colon - Sigmoid150.17
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0042775
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor